Drug Profile
Phenserine
Alternative Names: DWJ301; Phenserine tartrateLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator National Institute on Aging; National Institutes of Health (USA)
- Developer Cenomed BioSciences; Daewoong Pharmaceutical; QR Pharma
- Class Neuroprotectants; Nootropics; Phenylcarbamates; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein precursor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Poisoning
- Discontinued Cognition disorders
Most Recent Events
- 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in South Korea (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Poisoning in USA (PO)